The High Authority for Health announced on Tuesday in a press release that Kaftrio, a treatment deemed effective against cystic fibrosis, could now be administered to children aged 6 to 11, under certain conditions. Since June 2021, this treatment, considered by the associations as a “therapeutic revolution”, was covered by Social Security for patients in France, but was authorized only from the age of 12.
“The High Authority for Health (HAS) authorizes early access to a first treatment for children aged 6 to 11, but only those who are heterozygous for the F508del mutation of the CFTR gene and carriers of a mutation of this same minimal function gene”, specifies the instance, in its press release.
The treatment concerned consists of a combination of two drugs developed by the Vertex laboratory, Kalydeco and Kaftrio. According to the HAS, 288 children in France could benefit from it.